antitumor agent2

Antitumor agent-2 has anti-inflammatory and anti-tumor activity and can be used to study cancer.

Antitumor agent-200 (Compound 2g) is a microtubule synthesis inhibitor that binds to the colchicine site on tubulin, causing G2/M cell cycle arrest and inducing reactive oxygen species (ROS) production. It demonstrates significant inhibitory activity against P-glycoprotein (P-gp) overexpressing cell lines MCF7/ADR and KBV200, with resistance indices (DRI) of 0.83 and 0.58, respectively. In an MCF-7 xenograft model, Antitumor agent-200 (at 25 mg/kg, administered intraperitoneally) achieves a 57.2% tumor growth inhibition rate. This compound is applicable for research in the field of cancer therapy.

Antitumor agent-202 is a stabilizer of the p53Y220C mutant, selectively inhibiting the proliferation of tumor cells carrying the p53Y220C mutation. It is applicable for research focused on cancers associated with the p53 Y220C mutation.

Antitumor agent-201 (Compound 10) is a Golgi apparatus-targeting chloride ion transport activator with an EC50 for promoting transmembrane chloride ion transport of 1.53 mol% and an IC50 against HepG2 cells of 7.13 μM. By selectively acting on the Golgi apparatus, Antitumor agent-201 disrupts chloride ion homeostasis, decreases the expression of key proteins such as GM130 and GRASP55, and alters Golgi structure and function. This process induces Golgi apparatus autophagy, triggers apoptosis in cancer cells, and causes cell cycle arrest at the G2/M phase, thereby exhibiting anticancer activity. Antitumor agent-201 is applicable for research in the field of cancer-related diseases.

Antitumor agent-204 (compound 15a) is a potent antitumor drug with cytotoxic properties. It induces the release of nitric oxide (NO) and the production of reactive oxygen species (ROS). Additionally, Antitumor agent-204 triggers apoptosis and causes cell cycle arrest at the G2/M phase, demonstrating significant antitumor activity.

Antitumor agent-203 (compound 26) is a derivative of Exatecan (DX-8951) and serves as an ADC cytotoxin for antibody-drug conjugate (ADC) preparation.

Antitumor agent-209 (Compound 10g), a quinoline derivative, functions as an antineoplastic agent. It effectively inhibits the proliferation of various cancer cell lines, specifically HCT-116, RKO, DLD1, HepG2, BGC-823, NCI-H1650, and SK-OV-3, with IC50 values of 0.37, 0.58, 0.81, 0.79, 0.89, 0.78, and 0.89 μM, respectively.

Antitumor agent-208, an analog of Bufalin, is a potent and orally active antitumor agent. It exhibits antiproliferative activity against tumor cell lines with an IC50 of 0.30-1.09 nM. In MV-4-11 xenograft mouse models, Antitumor agent-208 inhibits tumor growth. It is applicable in cancer research, including studies on acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC).

Antitumor agent-205 (compound 9) is an Ecteinascidin derivative and an antitumor agent. It exhibits antiproliferative activity against A549 and HT29 cells, with a GI50 value of 16.4 nM for both cell lines. Antitumor agent-205 is applicable in the study of lung and colon cancer.

Antitumor agent-21 (TRX818) is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities.

Antitumor agent-28 is a compound that specifically targets and inhibits the activity of the ataxia telangiectasia mutated (ATM) kinase. By doing so, it effectively impedes the progression of ATM-mediated diseases and demonstrates significant anti-cancer activity.

Antitumor agent-23 exhibits potent antitumoral activity, as demonstrated by its GI50 values of 38, 48, 5, 27, 80, and 28 nM against the lymphoma cell lines GRANTA-519, KARPAS-422, KARPAS-299, RAMOS, DAUDI, and RAJI respectively.

Antitumor agent-29 is a hepatocyte-targeting prodrug with demonstrated efficacy and minimal toxicity in anticancer applications.